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Purpose: Despite advantages demonstrated in vitro, no single thrombolytic agent has been 
clearly shown to be superior to another in the clinical setting. Prouroklnase has recently 
received attention as a new thrombolytic agent with higher fibrin specificity. The 
thrombolytic activity of prourokinase, however, remains ill defined. The purpose of this 
study was to evaluate thrombolysis with prourokinase in comparison to urokinase in vitro. 
Methods: We used an in vitro parallel channel perfusion model that simulates catheter- 
directed thrombolysis in the peripheral arterial system. Radiolabeled thrombi were 
subjected to 90 minutes of endhole catheter-directed infusion with either prourokinase 
5000 IU/ml ,  urokinase 5000 IU/ml ;  or 5% dextrose in water at 4 ml/hr. 
Results: Prourokinase and urokinase were found to be equivalent with respect to 
thrombolytic effect. Percent lysis was maximal at 90 minutes in both the urokinase and 
prourokinase groups. Prourokinase and urokinase were found to be equally effective in 
restoring flow through thrombosed graft segments. 
Conclusions: Prourokinase appears to offer little benefit over urokinase with respect o 
thrombolytic activity in an in vitro model that closely resembles the clinical setting. I f  
prourokinase is to be accepted as an alternative to urokinase, advantages must relate to 
differences in fibrin specificity. (J VASC SURG 1996;23:657-66.) 
Intraarterial thrombolysis has proven to be a 
useful modality in the treatment of  acute arterial 
occlusion. Nilsson et al. ~ and Ouriel et alfl found 
thrombolysis to be equivalent to operation in terms 
of limb salvage, but mortality rates were significantly 
improved over those observed with operation. In 
addition, one third of  patients were spared operative 
intervention. Although thrombolysis has been  
shown to be effective therapy, the ideal thrombolytic 
agent has yet to be defined. I f  indeed there are 
meaningful differences between agents, they have 
been difficult to identify in clinical trials. Numerous 
factors render comparisons between trials difficult. A 
partial list of these factors includes retrospective 
versus prospective design; differences in patient 
selection; categorization of severity of ischemia and 
the age of occlusions; differences in the outcome of 
therapy, for example, clinical versus radiographic 
endpoints; and differences in the activities of dif- 
ferent preparations, dosing regimens, duration and 
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mode of administration of thrombolytic agent, and 
technique of catheter placement. 
Streptokinase was the initial thrombolytic agent 
investigated for use in peripheral arterial thromboly- 
sis. 3 Subsequently, numerous studies evaluating 
urokinase and recombinant tissue-type plasminogen 
activator (rt-PA) in comparison to streptokinase, and 
to each other, have been published) 13 
In the absence of clear-cut therapeutic advantages, 
urokinase has, in general, become the preferred agent 
for use in acute arterial occlusion. This is largely 
because of its economic advantages and reduced 
incidence of bleeding complicationss ,14-16 
Pro urokinase has recently received increased at- 
tention as a thrombolytic agent, although to date, the 
use ofprourokinase in acute arterial occlusion has not 
been reported. Prourokinase has been evaluated in 
comparison to urokinase in several animal models and 
in vitro. 7'17~36 However, no in vitro investigation has 
used whole blood as the milieu. 
We have previously described an in vitro parallel 
channel perfusion model for the study ofthromboly- 
sis that simulates, in vitro, catheter-directed throm- 
bolysis in the peripheral arterial system. 37 The purpose 
of this study was to evaluate thrombolysis with 
prourokinase in comparison to urokinase with this 
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Table I. Conditions during per fusions 
Hematocrit ACT Max flow Total flow Temperature BP 
DsW 39.3 + 2.9 248.4 -+ 41.8 75.5 + 8.0 200.9 + 11.0 37.0 + 0.2 130.0 _+ 6.6 
Urokinase 40.2 + 2.2 275.9 + 7.2 85.5 + 9.8 194.9 _+ 10.0 36.7 + 0.2 114.9 + 4.6 
Prourokinase 40.7 + 4.2 235.3 + 23.3 80.6 + 8.6 204.6 + 10.1 37.5 + 0.3 118.5 + 6.0 
p Value* NS NS NS NS 0.003 0.003 
*Singlc factor ANOVA. 
Values given as mean + standard eviation. 
BP, Blood pressure. 
model. The study incorporates data we have previ- 
ously published on urokinasc, s7 We report our expe- 
rience with prourokinasc, urokinase, and control (5% 
dextrose in water [D s W]) in this system. 
METHODS 
Material. Prourokinase, with an activity of 
109,000 fU /mg,  was provided by Abbott Laborato- 
ries, North Chicago, I11. The prourokinasc, 4 mg/ml,  
was diluted in DsW to a final concentration of 5000 
IU/ml.  Urokinase was supplied as Abbokinase (Ab- 
bott Laboratories ). The 250,000 IU vials were recon- 
stituted with 5 ml sterile water and frozen in 0.5 ml 
aliquots at -20 ~ C. Each aliquot was added to 5 ml 
DsW to achieve afinal concentration f5000 IU/ml.  
The dosage ofprourokinase and urokinasc used in this 
study was extrapolated from the dose of urokinase 
required clinically to lyse a typical thrombosed lower 
extremity bypass graft segmcnt measuring 6 mm x 40 
cm and was scaled down to the dimensions of the 
experimental clot-containing graft, 5 mm x 5 cm, by 
use of a simple proportion. The dosage of urokinasc 
f?om which the "scaling down" was performed was 
4000 IU/ml ,  which was based on the protocol 
established by McNamara and Fischer. 4
Groups studied. Radiolabeled thrombi were 
laced with 0.35 ml phosphate buffer and subjected to 
90 minutes of end-hole catheter-directed infusion 
with either prourokinase, 5000 IU /ml  (n= 10); 
urokinase, 5000 IU /ml  (n = 5); or DsW (n = 5), each 
at 4 ml/hr. The DsW group scryed as a control for the 
mechanical nd dilutional effects of  end-hole catheter 
infusion. 
Clot formation. Fourteen healthy human vol 
unteers (without a history ofnonsteroidal ntiinflam- 
matory or oral contraceptive use) donated 80 ml 
whole blood for each perfusion (n = 20) without 
repeat donors in any group. The expcrimental throm- 
bus was formed as previously described. 37 Briefly, 10 
ml whole blood was combined with 500 IU thrombin 
and 1.0 btCi iodine 125-labeled fibrinogen in a plastic 
syringe. Thrombi were incubated at 37 ~ C for 
90 minutes, removed ftom the syringe, cut into 
strips, and gently packed (after retraction) into 5 cm 
segments of 5 mm polytetrafluoroethylene grafts 
provided by W.L. Gore & Associates, Flagstaff; 
Ariz. 
Experiments. Pcrfusions were conducted in the 
University of Rochester Vascular Research Labora- 
tory. The prourokinase perfusions began in June 
1993 and continued our earlier work studying plas- 
minogen acceleration of urokinase thrombolysis. 37
Urokinase and DsW experiments began in December 
1992 as part of this work. 
Perfusion model. The perfusion circuit used in 
this study has been described in detail elsewhere, s7A 
brief outline of thc system is provided here for 
convenience. Our system is designed to closely repro- 
duce the conditions of peripheral arterial thromboly- 
sis. It uses 60 ml of heparinized whole blood (0.75 
IU/ml)  and a recirculating system that uses two 
parallel pathways; one containing a vascular graft 
occluded with thrombus, and the second containing 
a bypass circuit, simulating collateral arterial flow. 
Lytic agent or DsW is infused dircctly into thc 
thrombus by use of a volumetric infusion pump 
(PC-2; Imed, San Diego, Calif.), and an end-hole 
infusion catheter (outer diamctcr 1.1 mm) is inserted 
1 cm into the thrombus. Pulsatile flow in.the system 
is created by a peristaltic pump (Manostat; Varistaltic, 
Rochester, N.Y.). Flow is monitored by a digital flow 
meter calibrated to the pump and adjusted to main- 
tain a per fusion pressure close to normal arterial 
systolic pressure. Pressure is continuously monitored 
in-line by use of a Hewlctt-Packard transducer 
(Hewlett-Packard Co., Palo Alto, Calif:). Flow 
through the graft segment is measured continuously 
with an ultrasonic flow meter (Transonic Systems, 
Ithaca, N.Y.). The temperature of the circulating 
blood is maintained as close to normothermia s 
possible by enclosing the per fusion system in a heated, 
lead-lined box. Temperature in the box and of the 
perfusate is monitored continuously. To account for 
radioactivity lost f~om the system as a result of 
transudation of fluid through the interstices of the 
porous graft, the graft segment is suspended over a 
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Fig. 1. Percent clot lysis, determined by 125I release into perfusate. 
Table I I .  Percent clot lysis, determined by ~25I-release into perfusate 
Prourokinase Urokinase Control 
Time (min.) Mean lysis (%) 9,5% CI (+_) * Mean lysis (%) 95% CI (+_) Mean lysis (%) 9,5% CI  (+_) 
0 -1.631" 0.45 -0.01 0.48 -0.23 0.25 
1 0.20 0.81 -0.01 0.43 -0.21 0.27 
2 -0.01 0.76 -0.02 0.59 -0.19 0.49 
3 0.48 1.16 -0.04 0.34 -0.02 0.37 
5 0.70 1.46 0.07 0.47 0.34 0.44 
10 1.20 2.16 4.82 5.29 0.87 1.17 
15 2.50 4.59 5.15 7.01 0.66 1.44 
20 5.35 6.05 6.66 8.15 1.38 1.48 
25 8.201" 7.61 11.90 14.45 1.30 1.92 
30 11.64J" 9.91 13.90 15.32 1.33 2.00 
35 12.01"i" 9.12 16.94 18.52 1.42 2.05 
40 17.961" 11.98 19.04 19.27 1.61 2.07 
45 21.121" 14.53 21.32 22.22 2.20 2.45 
50 23.90 t 13.84 24.38 22.45 1.95 2.16 
55 26.771" 15.72 26.44 24.34 1.89 2.25 
60 32.901" 17.25 26.99 24.59 2.05 2.44 
65 31.13J" 14.92 29.07 25.02 2.19 2.61 
70 31.971" 14.69 31.28 26.54 2.26 2.33 
75 30.58" i  15.83 32.25J" 24.02 2.26 2.11 
80 32.19J" 14.46 34.981" 23.87 2.46 2.44 
85 34.76J" 16.00 37.46J" 23.73 2.58 2.61 
90 37.71"~ 16.54 42.351" 21.94 2.76 2.33 
CI, Confidence interval. 
*+2 (standard error of  the mean). 
~Compared with control, p < 0.05 (one-tail) for two-sample t test assuming unequal variance. 
100 ml water bath, a sample of which is taken at the 
end of each perfusion and counted. 
Activated clotting time was measured before and 
after administration of heparin. Hematocrit was de- 
termined on the heparinized blood. During each 
90-minute perfusion, measurements of total system 
flow, graft flow, temperature, and systolic blood pres- 
sure were recorded at 0, 1, 2, 3, and 5 minutes and 
at 5-minute intervals thereafter. In addition, 1 ml ali- 
quots were taken from the reservoir at the same inter- 
vals. These samples were obtained for determination 
of 125I activity with a gamma counter (TM Analytic, 
Bensenville, Ill.). From these samples, counts per mil- 
liliter ofperfusate were measured at set intervals, and 
from this figure, cumulative counts removed and per- 
cent clot lysed were calculated. After each perfusion 
the graft was removed from the system and recounted 
to quantitate the amount of residual thrombus. 
Statistics. Data from the groups were compared 
over time with analysis of variance and Student's ttest. 
Significance was assumed at p _< 0.05. The endpoints 
were calculated at each time interval and expressed as 
mean _ 2 times the standard error of the mean, that is 
the 95% confidence interval is presented. 
RESULTS 
Reliability. Table I illustrates the conditions dur- 
ing the perfusions. There were no significant differ- 
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Fig. 2. Percent flow through thrombus-filled graft segments. 
Tab le  I I I .  Percent flow through thrombus-f i l led graft segments 
Prourokinase Urokinase Control 
Time (min.) Mean flow (%) 95% CI (+) * Mean flow (%) 95% CI (+) Mean flow (%) 95% CI (+) 
0 0.04 0.11 0.22 0.40 0.00 0.00 
1 0.88 0.72 0.00 0.00 0.00 0.00 
2 0.17 0.13 0.00 0.00 0.00 0.00 
3 0.35 0.39 0.00 0.00 0.00 0.00 
5 0.46 0.33 0.00 0.00 0.00 0.00 
10 1.82 0.86 3.30 5.90 1.85 2.93 
15 4.00 1.61 3.85 4.53 1.63 2.29 
20 5.85 t 3.30 6.13 8.12 1.76 1.97 
25 7.06 3.90 13.03 9.97 2.38 1.66 
30 9.15 5.31 17.93 12.66 2.85 1.97 
35 11.11 t 7.69 19.01 t 12.16 2.98 1.84 
40 12.45]. 8.89 21.42 t 12.53 3.15 0.75 
45 9.77 9.67 22.05 12.26 3.40 0.65 
50 9.95 t 8.96 22.96 12.10 4.33 1.23 
55 10.29 9.67 22.73 t 12.36 5.47 2.58 
60 10.47 10.08 24.24]" 12.06 6.77 4.33 
65 10.80 9.80 25.79]" 11.35 7.48 4.68 
70 9.95 7.34 25.91]" 11.45 7.94 4.32 
75 10.29 6.99 19.28 16.73 7.32 4.17 
80 11.35 7.52 19.49 16.77 8.41 3.78 
85 10.85 6.77 21.73 15.29 9.40 4.75 
90 14.62 9.21 27.85 t 10.62 9.93 4.24 
CL Confidence interval. 
*+2 (standard error of the mean). 
tCompared with control, p < 0.05 (one-tail) for two-sample t tcst assuming uneqnal variance. 
ences in the hematocr it  or  activated clott ing time 
(ACT) of  the heparinized blood. Maximum flow, 
recorded when a nonocc luded graft was placed in the 
system, and mean total flow also did not  diffcr 
significantly between groups. 
There were significant differences in the mean 
temperature and b lood pressure. The mean tempera- 
ture during the prourokinase per fusions was 
37.5 + 0.3, which was significantly higher than that 
dur ing the DsW and urokinase perfusions, 37.0 + 0.2 
and 36.7 + 0.2, respectively, (p -- 0.02 andp -- 0.004: 
two tail t test). The mean temperatures during the 
urokinase and DsW perfusions did not  differ signifi- 
cantly (p  = 0.42: two-tai led t test). 
Mean b lood pressure during the urokinase and 
prourokinase perfusions, 114 .9+4.6  and 118.5 _+ 
6.0, did not  differ significantly (p= 0.26; two tail 
t-test). Mean b lood pressure during thc DsW perfu- 
sions, 130.0 _+ 6.6, was significantly higher than that 
dur ing thc nrokinase and prourokinase perfusions 
(p = 0.007 and p = 0.01: two-tai led t test). 
C lo t  lysis. Lysis in the control  perfusions re- 
maincd ncgligible (Fig. 1, Table I I) .  In contrast 
significant amounts o f  radiolabeled f ibrinogen ap- 
peared in the circulating blood after 25 minutes o f  
prourokinase infusion (p = 0.042, one-tai led t test). 
Near significant lysis was achieved after 40 minutes o f  
urokinase infusion (p = 0.09, one-tai led t test). Lysis 
with urokinasc became significant after 75 minutes 
(p = 0.045, one-tai led t test). Percent lysis was maxi- 
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mal at 90 minutes in both the urokinase and prouroki- 
nase groups. No significant differences inpercent lysis 
between the two thrombolytic agents were observed. 
Restoration o f  flow. The ability of the agents to 
restore flow through the clotted graft segments is 
demonstrated in Fig. 2 and Table III. Significant flow 
through the thrombosed graft segments was seen 
after 20 minutes of  prourokinase infusion (p= 
0.017). Flow with urokinasc became significant at 35 
minutes (p= 0.04, one tail t test). There was a 
significant diminution of  flow between 70 and 75 
minutes (p= 0.05), with restoration of flow at 90 
minutes. We have previously reported this phenom- 
enon and hypothesize that it may be a consequence of
cmbolization of thrombus and occlusion of the out- 
flow channel. 37 Similarly, a progressive diminution in 
the flow achieved with prourokinase was sccn occur- 
ring between 40 and 80 minutes; however, this failed 
to achieve statistical significance. During the control 
perfusions flow increased steadily, achieving a maxi- 
mum at 90 minutes. Paralleling the prourokinase and 
urokinase groups, a transient diminution in flow was 
seen, although this was not statistically significant. 
D ISCUSSION 
Clot lysis. Prourokinase and urokinase were 
found to be equivalent with respect o thrombolytic 
effect. Percent lysis was maximal at 90 minutes in both 
the urokinase and prourokinasc groups. Thromboly- 
sis with prourokinase, however, had a more rapid 
onset when compared with urokinase. Significant 
amounts of radiolabeled fibrinogen versus control 
appeared in the circulating blood after 25 minutes of 
prourokinase infusion (p = 0.042, one-tailed ttest) as 
compared with after 75 minutes of lysis with uroki- 
nase (p = 0.045, one-tailed t test). 
The validity of these findings is supported by 
several observations. Mean blood pressure during the 
DsW perfusions was greater than that during the 
urokinase and prourokinase perfusions. It can be 
hypothesized that the greater pressures during the 
DsW perfusions resulted in an augmentation of clot 
lysis as a result of the mechanical effects of increased 
pressure, resulting in a relative underestimation f  the 
effects ofurokinase and prourokinase. Mean pressure 
during the prourokinasc and urokinase perfusions was 
not statistically different. This is consistent with the 
finding of no difference in the thrombolytic effect of 
the agents. 
Mean temperature during the prourokinase per- 
fusions was greater than that during the DsW and 
urokinase perfusions. This could have accounted for 
the earlier lysis seen with prourokinase, because 
greater temperatures may have increased the rate of 
lysis and tended to magnify any differences between 
urokinase and prouroldnase. This observation pro- 
vides further support for the finding of lack of 
difference in the effectiveness of urokinase and 
prourokinase. Mean temperature during the uroki- 
nase pcrfusions was not statistically different than 
that during the D~W perfusions; therefore the dif- 
ferences een cannot be attributed to differences in 
temperature. 
Likewise, there were no significant differences in
the hematocrit or ACT of the heparinized blood. 
Maximum flow, recorded when a nonoccludcd graft 
was placed in the system, and mean total flow, also did 
not differ significantly between groups. As such, it is 
unlikely that these factors account for the differences 
observed in clot lysis. 
Flow. Prourokinase and urokinase were found to 
be equally effective in restoring flow through the 
thrombosed graft segments. Prourokinasc had a more 
rapid onset when compared with control. Flow was 
detected after 20 minutes ofprourokinase infusion as 
compared to 35 minutes with urokinase. Significant 
flow through the thrombosed graft segments was seen 
after 20 minutes of prourokinase infusion (p= 
0.017). Flow with urokinase became significant at 35 
minutes (p = 0.04, one-tailed t test). The effect of 
higher pressures during the control perfusions again 
could have resulted in an underestimation f  the ef- 
fects of the agents. The earlier estoration of flow seen 
with prourokinase can, as well, be attributed to higher 
mean temperatures during prourokinase perfusions. 
There was a trend toward higher flow with uroki- 
nase, which was observed at 70 minutes. This trend 
would not have been affected by differences in pres- 
sure but would have been diminished by the differ- 
ences in temperature that would have favored lysis 
with prourokinase. 
There was evidence of diminution of flow in both 
the urokinase and prourokinase groups despite ongo- 
ing lysis, as determined by the continued appearance 
of radiolabeled fibrinogen. As noted above, we hy- 
pothesize that this phenomenon may be a conse- 
quence ofembolization ofthrombus and occlusion of 
the outflow channe l J  In the aforementioned inves- 
tigation, the phenomenon of temporary reocclusion 
was observed with urokinase thrombolysis but was 
not sccn in the lysis of thrombi that had been 
previously laced with lys-plasminogen. I  the uroki- 
nase group, flow was reestabliShed after 15 minutes of 
continued perfusion. In this study a trend toward 
restoration of flow was seen at 90 minutes ofperfusion 
with prourokinase. 
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Tab le  IV .  In -v i t ro  invest igat ions  us ing  1251 p lasma c lot  lysis assays 
Findings Ref. Year Author Location Protocol Clot Milieu 
PUK = UK 18 1984 Gurewich Boston PUK (25-100 IU/ml )  x 22 ~ Plasma clot Buffer 
UK (200-1500 IU/ml )  x 22 ~ 
LMW-UK (200-1500 IU/ml)  x 22 ~ 
51 1984 Lijnen Leuven r-PUK (25 200 IU/ml )  x 4 ~ Plasma clot Plasma 
UK (25-200 IU/ml )  x 4 ~ 
r-UK (25-200 IU/ml )  x 4 ~ 
t-PA (5-30 IU /mt)  x 4 ~ 
29 1984 Zamarron Leuven r-PUK(0-200 IU/ml )  x 5 ~ Plasma clot Plasma 
r-UK, UK(0-200 IU/ml )  x 5 ~ 
t-PA (0-30 IU /ml )  x 5 ~ 
30 1986 Stump Leuven PUK (80 nm) x 4 ~ Plasma clot Plasma 
32k-PUK (45 nm) x 4 ~ 
UK (40 nm) x 4 ~ 
31 1986 Rijken Leiden 55 k-PUK (0-125 IU/ml)  x 10 ~ Plasma clot Heparinized 
Plasma 
30 k-PUK (0-170 IU/ml)  x 10 ~ 
UK(0-125 IU /ml )  x 10 ~ 
32 1987 Nelles Leuven PUK (60-480 ng/ml)  x 4 ~ Plasma clot Plasma 
UK (50 480 ng/ml)  x 4 ~ 
t-PA/PUK-hybrid (95-1500 ng/ml)  x 4 ~ 
t-PA/UK-hybrid (100-800 ng/ml)  x 4 ~ 
PUK (0-6,400 ng/ml)  x 4 ~ 21 1989 Sabovic Leuven Compressed Buffer 
plasma clot 
UK (0-6,400 ng/ml)  x 4 ~ 
t-PA (0-6,400 ng/ml)  x 4 ~ 
SK (0-6,400 ng/ml)  x 4 ~ 
23 1990 Sabovic Leuven PUK(200-1600 ng/ml)  x 4 ~ Compressed Plasma 
plasma clot 
UK (200-1600 ng/ml)  x 4 ~ 
t-PA (12-100 ng/ml)  x 4 ~ 
PUK > UK 18 1984 Gurewich Boston PUK (25-100 IU/ml )  x 22 ~ Plasma clot Plasma 
UK (200-1,500 IU/ml )  x 22 ~ 
LMW-UK (200-1500 IU/ml)  x 22 ~ 
19 1986 Pannell Boston PUK(65 IU/ml )  x 6 ~ Plasma clot Plasma 
UK (65 IU/ml )  x 6 ~ 
20 1989 Watahiki London PUK(10-1000 u/ml) x 5 ~ Plasma clot Plasma 
UK (10-1000 u/ml)  x 5 ~ 
t-PA (10-1000 u/ml)  x 5 ~ 
21 1989 Sabovic Leuven PUK (0-6,400 ng/ml)  x 4 ~ 
UK (0-6,400 ng/ml)  x 4 ~ 
PUK < UK 
t-PA (0-6,400 ng/ml)  x 4 ~ 
SK (0 6,400 ng/ml)  x 4 ~ 
Noncompressed Buffer 
plasma clot 
Compressed Plasma 
plasma clot 
22 1990 Bode Heidelberg PUK Plasma clot Plasma 
PUK-Fab' 
25 1986 Collen Leuven PUK (0 64 nm) x 4 ~ Plasma clot Plasma 
UK (0-64 rim) x 4 ~ 
t PA(0 64ran) x4  ~ 
19 1986 Pannell Boston PUK (65 IU/ml)  x 6 ~ Plasma clot Plasma 
UK (65 IU/ml )  x 6 ~ 
17 1987 Stump Leuven u-PUK (50-400 IU/cc) x 4 ~ Plasma clot Plasma 
c-PUK (20-160 IU/cc)  x 4 ~ 
32k-PUK (24-190 IU/cc) • 4 ~ 
UK(12 96 IU/cc)  x4  ~ 
20 1989 Watahiki London PUK (100 u/ml)  • 6 ~ Plasma clot Plasma 
UK(100 u/ml)  x 6 ~ 
t-PA (5 u/ml)  x 6 ~ 
26 1989 Dewerchin Leuven PUK(25-5000 ng/ml)  x 4 ~ Plasma clot Plasma 
UK (25-5000 ng/ml)  x 4 ~ 
21 1989 Sabovic Leuven PUK(0-6,400 ng/ml)  x 4 o Noncompressed Plasma 
plasma clot 
UK (0-6,400 ng/ml)  x 4 ~ 
t-PA (0-6,400 ng/ml)  • 40 
8K (0-6,400 ng/ml)  x 4 ~ 
27 1989 Lijnen Leuven PUK (0-5 gg/ml)  x 2 ~ Plasma clot Plasma 
UK (0-2 lag/ml) • 2 ~ 
PUK, Prourokinase; UK, urokinase; LMW-UK, low molecular weight urokinase. 
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Table  V. In vitro investigations with ~25I-labelled whole b lood clot lysis assays 
Findings Ref Year Author Location Protocol Clot Milieu 
PUK = UK 21 1989 Sabovic Leuven PUK (0-6,400 ng/ml) • 4 ~ Nonretracted whole blood clot Buff~:r 
UK (0-6,400 ng/ml) x 4 ~ 
t-PA (0-6,400 ng/ml) x 4 ~ 
SK (0-6,400 ng/ml) • 4 ~ 
PUK > UK 21 1989 Sabovic Leuven 
Retracted whole blood clot Buffer 
Retracted whole blood clot Plasma 
23 1990 Sabovic Lcuven Retracted whole blood clot Plasma 
PUK (0-6,400 ng/ml) x 4 ~ 
UK (0-6,400 ng/ml) x 4 ~ 
t-PA (0-6,400 ng/ml) • 4 ~ 
SK (0-6,400 ng/ml) x 4 ~ 
PUK (100-3200 ng/ml) x 4 ~ 
UK (200-1600 ng/ml) x 4 ~ 
t-PA (50-1600 ng/ml) x 4 ~ 
PUK (0-6,400 ng/ml) • 4 ~ 
UK (0-6,400 ng/ml) x 4 ~ 
t-PA (0-6,400 ng/ml) x 4 ~ 
SK (0-6,400 ng/ml) x 4 ~ 
PUK < UK 21 1989 Sabovic Leuven Nonretracted whole blood clot Plasma 
28 1987 Hanbucken Aachen PUK (25-100 PU/ml) x 180' Chandler loop whole blood clot Plasma 
UK (25-100 PU/ml) x 180' 
PUK, Prourokinase; UK, urokinase; t-PA, tissue plasminogcn activator; SK, streptokinase. 
Table  V I .  In vitro investigations with fibrin clot lysis assays 
Findings Ref Year Author Location Protocol Clot Milieu 
PUK > UK 24 1988 Pannell Boston PUK (300 ng/ml) • 6 ~ Fibrin clot Plasma 
UK (100 ng/ml) • 6 ~ 
PUK < UK 27 1989 Lijnen Leuven PUK (ng/ml) x 1 ~ Fibrin clot Plasma 
UK (ng/ml) x 1 ~ 
PUK (ng/ml) • 2 ~ Fibrin clot Plasma 
UK (ng/ml) x 2 ~ 
t-PA (ng/ml) x 2 ~ 
PUK, Prourokinasc; UK, urokinase; t-PA, tissue plasminogen activator. 
Again, the cft~ct o f  higher pressures during the 
DsW pcrfusions would have tended to minimize the 
differences seen with thrombolyt ic  agent when com- 
pared with control.  
P rourok inase  versus urok inase:  in v i t ro  s tud-  
ies. A direct comparison o f  the results presented in 
this study with those o f  the other  investigations 
incorporat ing ~2q-labelcd clot lysis assays is prob- 
lematic, as is comparison among previous studies. As 
i l lustrated in Tables IV to VI,  the experimental 
condit ions vary widely among studies and investi- 
gators. There are differences in the concentrat ion 
and specific activity o f  thrombolyt ic  agent, durat ion 
o f  experiment,  definition of  endpoints,  milieu, and 
method o f  clot formation. 
The majority o f  in vitro investigations comparing 
prourokinase with urokinase have used variations o f  
the 12q-labeled plasma clot lysis system described by 
Matsuo et al. 38 Much of  this work has been done by 
Collen et al.2s and Gurewich et al. 18 (Table IV). A 
smaller body o f  work exists regarditLg the evaluation 
of  thrombolyt ic  agents by use o f  whole b lood clots 
(Table V). A few studies report  results with fibrin clots 
(Table VI).  
This study used retracted whole b lood clots in a 
heparinizcd whole b lood milieu. As such, the most 
valid studies for comparison are probably those o f  
Sabovic et al.,21"2a who studied lysis of  retracted whole 
b lood clots and compressed plasma clots in a plasma 
milieu. Sabovic et al. 21'23 found that these clots, which 
arc serum-poor,  were relatively resistant o lysis as 
compared with noncompresscd plasma clots and 
nonretracted whole b lood clots. Furthermore,  Sabo- 
vic et at. 21"23 found that serum-poor  plasma or re- 
tracted whole b lood clots were very resistant o lysis 
with nonfibrin specific agents (urokinase and strep- 
tokinase). However,  serum-poor  plasma or retracted 
whole b lood clots were sensitive to lysis with fibrin- 
specific plasminogen activators (prourokinase and 
rt-PA). Sabovic et al. 21'23 hypothesized that plasma 
proteins entrapped in clots contr ibute significantly to 
their sensitivity to lysis and suggested that the amount  
of  bound or entrapped plasminogen may be a l imiting 
factor. In addit ion, Sabovic et al. 21 hypothesized that 
dur ing clot lysis with fibrin-specific agents (prourold- 
nase and rt-PA), plasminogen recruited from sur- 
rounding plasma may contr ibute significantly to clot 
lysis. 
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We did not demonstrate such a difference between 
prourokinase and urokinase. A number of factors may 
account for this finding. Sabovic's 2m3 experiments 
defined fibrinolytic potency as that concentration of 
plasminogen activator required to produce 50% clot 
lysis at 2 hours. Our perfusions were 90 minutes in 
duration and resulted in a maximum mean clot lysis of 
33.9% and 42% for prourokinase and urokinase, 
respectively. It is possible that, if the perfusions were 
of longer duration, greater differences would have 
been observed. 
In Sabovic's 21'2"~ experiment a prourokinase con- 
centration of 3200 ng/ml  was required to produce 
50% lysis of retracted blood clots in 2 hours. This is 
equivalent to 114.4 IU/ml .  39 Our perfusions used 
concentrations of plasminogen activator several or- 
ders of magnitude greater. Median concentrations 
were approximately 310 IU /ml  total system volume 
and 15,306 IU/ml  graft volume. 
Teleologically it might be anticipated that the 
higher doses would have resulted in a greater degree 
of clot lysis. However, this was not the case. The 
degree oflysis observed was moderate, and no difikr- 
ence was seen between prourokinase and urokinase. 
This may have been a consequence of the higher 
doses used. Clinically, doses in the 4.7 to 9 million 
units range have resulted in reduction of fibrinogen, 
0~2-antiplasmin , and plasminogen to levels 58%, 38%, 
and 21% of baseline.4~ Assuming a blood volume of 
4900 ml, these doses correspond to 959 to 1837 
IU/ml ,  which is within the range of the doses used in 
this study. It seems reasonable to conjecture that in 
our model similar reductions in fibrinogen, ct2-anti- 
plasmin and plasminogen may have occurred. Plas- 
minogen levels may have been depleted to levels 
inadequate for lysis. Falling 0~2-antiplasmin levels 
could have produced a disinhibition of urokinase- 
mediated lysis, causing an increase in nonspecific 
activation of plasma factors, further educing available 
plasminogen and decreasing local thrombolytic ef- 
fkct. Such mechanisms would account for the lack of 
difference between the two agents een in this model. 
Future investigations incorporating measurements of 
fibrinogen, ~2-antiplasmin and plasminogen would 
need to be done to investigate the validity of this 
hypothesis. 
Sabovic et al. 2~ found no difference between 
urokinase and prourokinase when lysis of retracted 
whole blood clots was performed ina buffer milieu. In 
plasma, however, greater lysis was seen with prouroki- 
nase. 23 It is conceivable that in this model as well, 
nonspecific activation of plasma factors accounted for 
the lack of difference seen. 
Although there are clearly difficulties in extrapo- 
lating from any in vitro investigation, we believe our 
model provides a valid basis for the comparison of 
agents because we attempt o reproduce the condi- 
tions of thrombolysis in the clinical setting. The 
dosages and mode of delivery of agent reflect hose 
used clinically. Conditions of flow and pressure are 
maintained within the physiological range. In addi- 
tion, we use retracted whole blood clots in a heparin 
ized whole blood milieu. 
Prourokinase versus urokinase: in vivo and 
clinical studies. We found prourokinase to be no 
more effective than urokinase in vitro. Prourokinasc 
has also been evaluated in comparison to urokinasc in 
several animal models. 17'~8'28'33 36 These studies uni 
fbrmly demonstrated the higher fibrin specificity of 
prourokinasc. Prourokinasc produced less fibrino- 
gcn, a2-antiplasmin and plasminogcn consumption 
than urokinase. Prourokinase was found to be more 
effective than urokinasc in a rabbit modcl of jugular 
venous thrombosis, ~7'33,34 as well as in rabbit and 
canine models of pulmonary embolus. 18 However, in 
another rabbit pulmonary embolus model, prouroki- 
nase was found to be no more effective than uroki 
nase. 28 Prourokinase was found to be less effective 
than urokinasc in both canine and baboon models of 
coronary artery occlusion. 3"~'36 
To date, the use ofprourokinase in acute arterial 
occlusion has not been reported. Prourokinase has 
been studied in volunteers and in patients with 
acute myocardial infarction. Again, all studies report 
less fibrinogen, c~2-antiplasmin , and plasminogen 
consumption with prourokinase than with uroki- 
nase.40'42'43 Prourokinase was found to be more effec- 
tive than urokinase in a randomized, ouble-blinded 
multicenter study of" intracoronary thrombolysis in 
acute myocardial infhrction. 44 In human volunteers, 
prourokinase and urokinase were found to produce 
comparable degrees of fibrinolysis. 4s Prourokinase 
has also been found to be synergistic in combination 
with urokinase or  r t -PA .  41'46-48 
The advantages of prourokinase seen in clinical 
trials may in part be a reflection of the effects of 
hepatic learance of accumulated thrombolytic agent 
and breakdown products of plasma factors. The lack 
of a route for the elimination of such factors is an 
inherent limitation of  this and other in vitro investi- 
gations. Whereas in vivo investigations might theo- 
retically overcome this limitation, animal species have 
in general been found to have relatively low sensitivity 
to human plasminogen activators. 28'49,s~ 
Our findings are in accordance with those studies 
that have found prourokinase to be of no greater 
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thrombolyt i c  potency  than urokinase. I f  v iewed on 
this basis alone, further  clinical invest igat ion with 
prourok inase may not  prove to be a wor thwh i le  
endeavor.  However ,  the l i terature has un i formly  dem- 
onstrated the high ratio o f  f ibrinolytic to f ibrino- 
genolyt ic  activity o f  prourok inase and therefore its 
potent ia l ly greater  safety. Accordingly,  prourok inase 
merits fur ther  invest igat ion in the sett ing o f  acute 
arterial occlusion. 
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